Association between hyperglycemia and hospital length of stay in patients undergoing hematopoietic stem cell transplantation

Endocrinologist

Volumn 20, Issue 5, 2010, Pages 232-235

  Rentschler, Lindsey M ^a   Swarts, Sarah J ^b   Bierman, Philip J ^a   Devetten, Marcel P ^a   Stoner, Julie A ^c   Puumala, Susan E ^d   Goldner, Whitney S ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b CentraCare Clinic   (United States)

^c UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^d UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

hematopoietic stem cell transplant; hyperglycemia; insulin; intensive glycemic control; TPN

Indexed keywords

CYCLOSPORIN; MYCOPHENOLIC ACID; TACROLIMUS;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HYPERGLYCEMIA; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; POSTOPERATIVE COMPLICATION; POSTOPERATIVE INFECTION; RISK FACTOR; TOTAL PARENTERAL NUTRITION; TREATMENT OUTCOME;

EID: 77957571626     PISSN: 10512144     EISSN: None     Source Type: Journal    
DOI: 10.1097/TEN.0b013e3181f47dbc     Document Type: Article

References (29)

1. Van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in critically ill patients. N Engl J Med. 2001;345:1359-1367.
2. Capes S, Hunt D, Malmberg K, et al. Stress hyperglycemia and prognosis of stroke in non-diabetic and diabetic patients. Stroke. 2001;32:2426-2432.
3. Malmberg K. Prospective randomized study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. BMJ. 1997;314:1512-1515.
4. Malmberg K, Ryden L, Efendic S, et al. Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year. J Am Coll Cardiol. 1995;26:57-65.
5. Golden SH, Peart-Vigilance C, Kao WH, et al. Perioperative glycemic control and the risk of infectious complications in a cohort of adults with diabetes. Diabetes Care. 1999;22:1408-1414.
6. Malmberg K, Norhammar A, Wedel H, et al. Glycometabolic state at admission: important risk factor of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction: long term results from the diabetes and insulin-glucose infusion in acute myocardial infarction (DIGAMI) study. Circulation. 1999;99:2626-2632.
7. Hammer M, Casper C, Gooley T, et al. The contribution of malglycemia to mortality among allogeneic hematopoietic cell transplant recipients. Biol Blood Marrow Transplant. 2009;15:344-351.
8. Umpierrez G, Isaacs S, Bazargan N, et al. Hyperglycemia: an independent marker of in-hospital mortality in patients with undiagnosed diabetes. J Clin Endocrinol Metab. 2002;87:978-982.
9. Sala J, Masia R, Gonzalez de Molina F, et al. Short term mortality of myocardial infarction patients with diabetes or hyperglycaemia during admission. J Epidemiol Community Health. 2002;56:707-712.
10. Furnary A, Zerr K, Grunkmeier G, et al. Continuous intravenous insulin infusion reduces the incidence of deep sternal wound infection in diabetic patients after cardiac procedures. Ann Thorac Surg. 1999;67:352-362.
11. Bolk J, van der Ploeg T, Cornel JH, et al. Impaired glucose metabolism predicts mortality after a myocardial infarction. Int J Cardiol. 2001;79:207-214.
12. ACE/ADA Task Force on Inpatient Diabetes. American College of Endocrinology and American Diabetes Association Consensus statement on inpatient diabetes and glycemic control. Diabetes Care. 2006;29:1955-1962.
13. Van den Berghe G, Wilmer A, Milants I, et al. Intensive insulin therapy in mixed medical/surgical intensive care units: benefit versus harm. Diabetes. 2006;55:3151-3159.
14. Van den Berghe G, Wilmer A, Hermans G, et al. Intensive insulin therapy in the medical ICU. N Engl J Med. 2006;354:449-461.
15. Krinsley J. Effect of an intensive glucose management protocol on the mortality of critically ill adult patients. Mayo Clin Proc. 2004;79:992-1000.
16. The NICE-SUGAR Study Investigators. Intensive versus conventional glucose control in critically ill patients. N Engl J Med. 2009;360:1283-1297.
17. Sheean PM, Braunschweig C, Rich E. The incidence of hyperglycemia in hematopoietic stem cell transplant recipients receiving total parental nutrition: a pilot study. J Am Diet Assoc. 2004;104:1352-1360.
18. Amin P, Shah S, Walker D, et al. Adverse metabolic and cardiovascular risk following treatment of acute lymphoblastic leukaemia in childhood: two case reports and a literature review. Diabet Med. 2001;18:849-853.
19. Jacobson P, Uberti J, Dabis W, et al. Tacrolimus: a new agent for the prevention of graft versus host disease in hematopoietic stem cell transplantation. Bone Marrow Transplant. 1998;22:217-225.
20. Taskinen M, Saarinen-Pihkala U, Hovi L, et al. Impaired glucose tolerance and dyslipidaemia as late effects after bone-marrow transplantation in childhood. Lancet. 2000;356:993-997.
21. Lorini R, Cortona L, Scaramuzza A, et al. Hyperinsulinemia in children and adolescents after bone marrow transplantation. Bone Marrow Transplant. 1995;15:873-877.
22. Muscaritoli M, Conversano L, Torelli G, et al. Clinical and metabolic effects of different parenteral nutrition regimens in patients undergoing allogeneic bone marrow transplantation. Transplantation. 1998;66:610-616.
23. Cheung NW, Zaccaria C, Napier B, et al. Hyperglycemia is associated with adverse outcomes in patients receiving total parenteral nutrition. Diabetes Care. 2005;28:2367-2371.
24. Sheean P, Freels S, Helton WS, et al. Adverse clinical consequences of hyperglycemia from total parenteral nutrition exposure during hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2006;12:656-664.
25. Garg R, Alyea E, Bhutani H, et al. Hyperglycemia and length of stay in patients hospitalized for bone marrow transplantation. Diabetes Care. 2007;30:993-994.
26. American Diabetes Association. Standards of medical care in diabetes-2008. Diabetes Care. 2008;31: S12-S55.
27. Vogelzang M, Hoekstra M, Drost J, et al. The impact of a reduced dose of dexamethasone on glucose control after coronary artery bypass surgery. Cardiovasc Diabetol. 2007;6:39-44.
28. Araki M, Flechner SM, Ismail HR, et al. Post-transplant diabetes mellitus in kidney transplant recipients receiving calcineurin inhibitors or mTOR inhibitor drugs. Transplantation. 2006;81:335-341.
29. Weiser M, Cabanillas M, Konopleva M, et al. Relation between the duration of remission and hyperglycemia during induction chemotherapy for acute lymphocytic leukemia with a hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone/methotrexate-cytarabine regimen. Cancer. 2004;100:1179-1185. (Pubitemid 38325945)